KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth.

Animals Aspartic Acid / metabolism Biological Transport, Active Carcinoma, Pancreatic Ductal / metabolism Cell Line, Tumor Cytosol / metabolism Female Glutamine / metabolism Humans Mice Mice, SCID Mitochondria / metabolism NADP / metabolism Oxidation-Reduction Pancreatic Neoplasms / metabolism Proto-Oncogene Proteins p21(ras) / metabolism Reactive Oxygen Species / metabolism Uncoupling Protein 2 / metabolism Xenograft Model Antitumor Assays

Journal

Nature metabolism

ISSN: 2522-5812

Titre abrégé: Nat Metab

Pays: Germany

ID NLM: 101736592

Informations de publication

Date de publication:
12 2020

Historique:

received: 14 09 2019

accepted: 22 10 2020

pubmed: 25 11 2020

medline: 6 1 2021

entrez: 24 11 2020

Statut: ppublish

Résumé

The oncogenic KRAS mutation has a critical role in the initiation of human pancreatic ductal adenocarcinoma (PDAC) since it rewires glutamine metabolism to increase reduced nicotinamide adenine dinucleotide phosphate (NADPH) production, balancing cellular redox homeostasis with macromolecular synthesis

Identifiants

DOI: 10.1038/s42255-020-00315-1 PMID: 33230296

pubmed: 33230296

doi: 10.1038/s42255-020-00315-1

pii: 10.1038/s42255-020-00315-1

doi:

Substances chimiques

KRAS protein, human 0

Reactive Oxygen Species 0

UCP2 protein, human 0

Uncoupling Protein 2 0

Glutamine 0RH81L854J

Aspartic Acid 30KYC7MIAI

NADP 53-59-8

Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

1373-1381

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)

ID : IG 2014 Id.15404

Pays : International

Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research)

ID : 2017PAB8EM_002

Pays : International

Références

Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656–670 (2012).

pubmed: 22541435 pmcid: 3472002

Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101–105 (2013).

pubmed: 23535601 pmcid: 3656466

Hensley, C. T., Wasti, A. T. & DeBerardinis, R. J. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J. Clin. Invest. 123, 3678–3684 (2013).

pubmed: 23999442 pmcid: 3754270

Altman, B. J., Stine, Z. E. & Dang, C. V. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat. Rev. Cancer 16, 619–634 (2016).

pubmed: 27492215 pmcid: 5484415

DeBerardinis, R. J. et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA 104, 19345–19350 (2007).

pubmed: 18032601

Abrego, J. et al. GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells. Cancer Lett. 400, 37–46 (2017).

pubmed: 28455244 pmcid: 5488721

Chakrabarti, G. et al. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by β-lapachone. Cancer Metab. 3, 12 (2015).

pubmed: 26462257 pmcid: 4601138

Wang, Y.-P. et al. Arginine methylation of MDH1 by CARM1 inhibits glutamine metabolism and suppresses pancreatic cancer. Mol. Cell 64, 673–687 (2016).

pubmed: 27840030

Vozza, A. et al. UCP2 transports C4 metabolites out of mitochondria, regulating glucose and glutamine oxidation. Proc. Natl Acad. Sci. USA 111, 960–965 (2014).

pubmed: 24395786

Pecqueur, C. et al. Uncoupling protein 2, in vivo distribution, induction upon oxidative stress, and evidence for translational regulation. J. Biol. Chem. 276, 8705–8712 (2001).

pubmed: 11098051

Rupprecht, A., Moldzio, R., Mödl, B. & Pohl, E. E. Glutamine regulates mitochondrial uncoupling protein 2 to promote glutaminolysis in neuroblastoma cells. Biochim. Biophys. Acta, Bioenerg. 1860, 391–401 (2019).

Nübel, T. et al. Modified glutamine catabolism in macrophages of Ucp2 knock-out mice. Biochim. Biophys. Acta 1777, 48–54 (2008).

pubmed: 18054322

Donadelli, M., Dando, I., Fiorini, C. & Palmieri, M. UCP2, a mitochondrial protein regulated at multiple levels. Cell. Mol. Life Sci. 71, 1171–1190 (2014).

pubmed: 23807210

Bouillaud, F., Couplan, E., Pecqueur, C. & Ricquier, D. Homologues of the uncoupling protein from brown adipose tissue (UCP1): UCP2, UCP3, BMCP1 and UCP4. Biochim. Biophys. Acta 1504, 107–119 (2001).

pubmed: 11239488

Palmieri, L. et al. Citrin and aralar1 are Ca2

pubmed: 11566871 pmcid: 125626

Owen, O. E., Kalhan, S. C. & Hanson, R. W. The key role of anaplerosis and cataplerosis for citric acid cycle function. J. Biol. Chem. 277, 30409–30412 (2002).

pubmed: 12087111

Alkan, H. F. et al. Cytosolic aspartate availability determines cell survival when glutamine is limiting. Cell Metab. 28, 706–720.e6 (2018).

pubmed: 30122555 pmcid: 6390946

Yoo, H. C. et al. A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells. Cell Metab. 31, 267–283.e12 (2020).

pubmed: 31866442

Dalla Pozza, E. et al. Role of mitochondrial uncoupling protein 2 in cancer cell resistance to gemcitabine. Biochim. Biophys. Acta 1823, 1856–1863 (2012).

pubmed: 22705884

Lee, W. D., Mukha, D., Aizenshtein, E. & Shlomi, T. Spatial-fluxomics provides a subcellular-compartmentalized view of reductive glutamine metabolism in cancer cells. Nat. Commun. 10, 1351 (2019).

pubmed: 30903027 pmcid: 6430770

Cavero, S. et al. Identification and metabolic role of the mitochondrial aspartate-glutamate transporter in Saccharomyces cerevisiae. Mol. Microbiol. 50, 1257–1269 (2003).

pubmed: 14622413

Porcelli, V. et al. Molecular identification and functional characterization of a novel glutamate transporter in yeast and plant mitochondria. Biochim. Biophys. Acta Bioenerg. 1859, 1249–1258 (2018).

pubmed: 30297026

Palmieri, F. Mitochondrial transporters of the SLC25 family and associated diseases: a review. J. Inherit. Metab. Dis. 37, 565–575 (2014).

pubmed: 24797559

Monné, M., Miniero, D. V., Iacobazzi, V., Bisaccia, F. & Fiermonte, G. The mitochondrial oxoglutarate carrier: from identification to mechanism. J. Bioenerg. Biomembr. 45, 1–13 (2013).

pubmed: 23054077

Tessa, A. et al. Identification of novel mutations in the SLC25A15 gene in hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome: a clinical, molecular, and functional study. Hum. Mutat. 30, 741–748 (2009).

pubmed: 19242930

Fiermonte, G. et al. An adult with type 2 citrullinemia presenting in Europe. N. Engl. J. Med. 358, 1408–1409 (2008).

pubmed: 18367750

Palmieri, L. et al. Identification in Saccharomyces cerevisiae of two isoforms of a novel mitochondrial transporter for 2-oxoadipate and 2-oxoglutarate. J. Biol. Chem. 276, 1916–1922 (2001).

pubmed: 11013234

Palmieri, F. The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflugers Arch. 447, 689–709 (2004).

pubmed: 14598172

Cassago, A. et al. Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. Proc. Natl Acad. Sci. USA 109, 1092–1097 (2012).

pubmed: 22228304

Baffy, G. Uncoupling protein-2 and cancer. Mitochondrion 10, 243–252 (2010).

pubmed: 20005987

Gao, J. et al. Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR. BMJ Open 6, e009532 (2016).

pubmed: 26747035 pmcid: 4716245

Rudin, C. M. et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44, 1111–1116 (2012).

pubmed: 22941189 pmcid: 3557461

Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–1101 (2005).

pubmed: 15718470

Wiederschain, D. et al. Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle 8, 498–504 (2009).

pubmed: 19177017

Barger, C. J., Branick, C. & Chee, L. & Karpf, A. R. Pan-cancer analyses reveal genomic features of FOXM1 overexpression in cancer. Cancers (Basel) 11, 251 (2019).

Lou, E. et al. Tunneling nanotubes provide a unique conduit for intercellular transfer of cellular contents in human malignant pleural mesothelioma. PLoS ONE 7, e33093 (2012).

pubmed: 22427958 pmcid: 3302868

Wach, A. PCR-synthesis of marker cassettes with long flanking homology regions for gene disruptions in S. cerevisiae. Yeast 12, 259–265 (1996).

pubmed: 8904338

Agrimi, G., Russo, A., Scarcia, P. & Palmieri, F. The human gene SLC25A17 encodes a peroxisomal transporter of coenzyme A, FAD and NAD

pubmed: 22185573

Bustin, S. A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25, 169–193 (2000).

pubmed: 11013345

Kushnirov, V. V. Rapid and reliable protein extraction from yeast. Yeast 16, 857–860 (2000).

pubmed: 10861908

De Marcos Lousa, C., Trézéguet, V., Dianoux, A.-C., Brandolin, G. & Lauquin, G. J. The human mitochondrial ADP/ATP carriers: kinetic properties and biogenesis of wild-type and mutant proteins in the yeast S. cerevisiae. Biochemistry 41, 14412–14420 (2002).

pubmed: 12450408

Li, Y. et al. Functional characterization of the partially purified Sac1p independent adenine nucleotide transport system (ANTS) from yeast endoplasmic reticulum. J. Biochem. 164, 313–322 (2018).

pubmed: 29893873 pmcid: 7109914

Vozza, A. et al. Biochemical characterization of a new mitochondrial transporter of dephosphocoenzyme A in Drosophila melanogaster. Biochim. Biophys. Acta Bioenerg. 1858, 137–146 (2017).

pubmed: 27836698

Badea, L., Herlea, V., Dima, S. O., Dumitrascu, T. & Popescu, I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 55, 2016–2027 (2008).

pubmed: 19260470

Pei, H. et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16, 259–266 (2009).

pubmed: 19732725 pmcid: 2755578

Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).

pubmed: 3320027 pmcid: 3320027

Donahue, T. R. et al. Integrative survival-based molecular profiling of human pancreatic cancer. Clin. Cancer Res. 18, 1352–1363 (2012).

pubmed: 22261810

Van den Broeck, A., Vankelecom, H., Van Eijsden, R., Govaere, O. & Topal, B. Molecular markers associated with outcome and metastasis in human pancreatic cancer. J. Exp. Clin. Cancer Res. 31, 68 (2012).

pubmed: 22925330 pmcid: 3511800

Winter, C. et al. Google goes cancer: improving outcome prediction for cancer patients by network-based ranking of marker genes. PLoS Comput. Biol. 8, e1002511 (2012).

pubmed: 22615549 pmcid: 3355064

Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).

pubmed: 16199517 pmcid: 16199517

Puleo, F. et al. Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology 155, 1999–2013.e3 (2018).

pubmed: 30165049

Marchi, S., Bonora, M., Patergnani, S., Giorgi, C. & Pinton, P. Methods to assess mitochondrial morphology in mammalian cells mounting autophagic or mitophagic responses. Methods Enzymol. 588, 171–186 (2017).

pubmed: 28237100

Divakaruni, A. S. et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc. Natl Acad. Sci. USA 110, 5422–5427 (2013).

pubmed: 23513224

Young, J. D., Allen, D. K. & Morgan, J. A. Isotopomer measurement techniques in metabolic flux analysis II: mass spectrometry. Methods Mol. Biol. 1083, 85–108 (2014).

pubmed: 24218212